HAL Allergy Group is active in the field of biopharmaceuticals and is located at the Bio Science Park in Leiden, The Netherlands. Our core business is the development and manufacturing of therapies and diagnostics for allergic diseases. In addition, we offer contract manufacturing services focusing on the production of biopharmaceutical products for (pre-) clinical studies. With offices in major European countries, HAL Allergy is one of the European top players in the allergy immunotherapy business. Established in 1959 HAL Allergy has long experience in developing, producing and selling allergy therapies with an immuno-modulatory effect causing a reduction in symptoms and long-term disease suppression. The allergy therapies are used against common allergies such as hay fever, house dust mites allergy and allergic reactions towards wasp or bee stings. More information is available on: http://www.hal-allergy.com.
The main shareholder of HAL Allergy GmbH is Droege International Group AG, which is an independent Advisory and Investment Company, based in Düsseldorf, Germany. More information is available on: http://www.droege-group.com.
Contact Details
HAL Allergy
J.H. Oortweg 15-17
2333 CH Leiden
The Netherlands
Tel. +31 (0) 88 1959 000
e-mail: info@hal-allergy.com
Twitter: https://twitter.com/hal_allergy
A well-established player in the Allergy market, the Dutch company HAL Allergy recently expanded its activities with the addition of its HALIX Contract Manufacturing Outsourcing (CMO) arm. CEO Harry Flore…
Our meetings frequently bring us here to the Leiden Bio Science Park, but more often than not, to meet with younger, up-and-coming companies. HAL Allergy, meanwhile, has a rich and…
Sanofi’s new CEO Belén Garijo has taken the reins of a company with healthy growth, but three recent late-stage clinical trial failures and a looming patent cliff for its biggest…
RNA interference (RNAi) therapeutics have the potential to redefine how certain diseases may be treated in the future, shifting the focus from managing symptoms to addressing their underlying biological cause.…
Dr Gertrud Demmler of SBK, one of Germany’s largest statutory health insurance funds, describe the EUR 18 billion funding gap facing the country’s health system, what the July 2026 GKV…
The future of Europe’s pharmaceutical industry will be shaped as much by manufacturing and industrial policy as by scientific innovation. Theodore Tryfon outlines how ELPEN is investing to strengthen healthcare…
Tom Shea, Founder and CEO of Meitheal Pharmaceuticals, discusses his career across commercial and operational roles in generic injectables and the creation of Meitheal in 2017. He highlights the company’s…
When, in his 2023 policy address, Hong Kong Chief Executive John Lee announced the territory’s intention to conduct its own primary reviews of medicines, the initial industry reaction was mixed.…
Strong patent portfolios can create substantial commercial value for biopharma companies. As Isobel Barry, partner at life sciences-focused IP firm Carpmaels & Ransford LLP explains, opportunities to patent new small…
The goal is not only to generate scientific breakthroughs, but to ensure that these breakthroughs reach patients faster and more reliably Professor Gerd Geisslinger serves as Chair of Clinical Pharmacology…
Across the Global South, hundreds of millions of people live without reliable access to basic healthcare. Too few doctors, too little data, and systems too fragile to scale. However, as…
Excalipoint is betting that the next chapter of T-cell engagers will be written in solid tumours, where the modality is beginning to challenge the boundaries of cancer immunotherapy. Co-Founder, Chairman…
Vaxcellbio aims to become a genuine game changer in the global immune cell therapy market Dr Je-Jung Lee, CEO of Vaxcellbio, discusses how his experience as a physician and immunotherapy…
Successive American governments have grappled with the need to contain spiraling healthcare costs while sustaining the USA’s well-earned reputation as the number one launch market for breakthrough medical innovations. “The…
China has rapidly become the world’s leading country for clinical trial volume, alongside the stratospheric growth of its local biotech industry, which now accounts for almost a third of the…
Our mission has remained constant: to develop and provide cancer patients with precise treatment and early detection, and to improve patient outcomes Dr. Tae-You Kim, CEO and Co-Founder of IMBdx,…
Brendan Shaw maps the global fallout from the Trump Administration’s Most Favoured Nation drug pricing agenda. From stalled launches to rattled health ministries, Shaw argues that MFN has thrown pharmaceutical…
The opportunity is not simply to replicate the US model, but to understand what works in each system and build on the strengths we already have in Europe After almost…
If you concentrate on shared goals, collaboration and a unified voice follow naturally. Youngshin Lee, CEO of KRPIA, has built a career spanning more than three decades across pharmaceutical R&D,…
Dr Yuan-Hung Hsu, President of MegaPro Biomedical, discusses the Taiwanese company’s evolution into a late-stage nanomedicine company, with two platforms targeting precision medicine. He highlights MPB 1523, a heavy-metal-free MRI…
As the European Medicines Agency navigates the most significant expansion of its mandate in a generation, Executive Director Emer Cooke highlights how the regulator is further strengthening its role across…
As global pharmaceutical companies diversify their manufacturing networks and seek trusted development partners, Taiwan’s CDMO sector is moving into sharper international focus. Drawing on decades of experience building ScinoPharm into…
Biotechnology has long been a strategic priority for Taiwan’s economic development, standing alongside ICT and semiconductors as a key pillar of growth for the island. Driven by a highly educated…
Korea, the world’s 13th-largest pharma market, is rolling out its biggest reform to pharma pricing in a generation, slashing what it pays for generics and using the savings to get…
Dr Holm Graessner has spent more than 20 years building the infrastructure that rare disease patients in Europe often lack entirely: diagnostic pathways, European reference networks, and academic drug development…
Demand for plasma-derived medicines continues to rise, bringing renewed attention to manufacturing capacity, supply resilience and the need for stronger plasma ecosystems. As Biotest enters its next phase of growth,…
Dr Toshiaki Nagafuji leads the Innovative Drug Development Business (IDDB) at Linical after a career spanning discovery and research at Chugai and clinical development, project management, and business development at…
Yeul Hong Kim, R&D President of Yuhan, discusses the company’s transformation from a traditional Korean pharmaceutical business into an increasingly global innovator. He outlines Yuhan’s open innovation strategy, pipeline focus,…
Money follows the science, and the science here in Bavaria is excellent Ralf Huss, Chief Executive of BioM, discusses how Bavaria has built one of Europe’s leading biotechnology ecosystems by…
Building stronger bridges between Korean biotech companies and global capital will be critical to unlocking the ecosystem’s full potential Chang Woo Lee, CEO of CUROGEN, discusses translating academic science into…
Prof. Fatma Al Jasmi, Professor of Biochemical Genetics at the UAE University’s College of Medicine & Health Science and the UAE’s first biochemical genetics consultant, has spent nearly two decades…
Jay Iyer, CEO of the Access to Medicine Foundation, warns that rising nationalism and “onshoring” risk dismantling decades of progress in global health. As geopolitical tensions reshape how drugs are…
Leadership in today’s pharmaceutical industry is no longer defined solely by the strength of a pipeline, but by the ability to anticipate change, execute consistently and adapt at scale. As…
Daniel Camardo is the President of Immedica Pharma US Inc. (Immedica), the US affiliate/subsidiary of Immedica Pharma AB, a Sweden-based rare disease company that entered the American market in 2024.…
Neuroscience is back. After a litany of divestments and scale backs in the 2010s, diseases of the brain are now the second-most-funded area in biotech, behind only cancer. However, this…
Over three decades at Terumo, Takuya Hosogai has seen the Group evolve across businesses, markets and technologies. Now leading Terumo Europe, he discusses the region’s growing role in Pharmaceutical Solutions…
My message is simply to continue believing in Europe Growth creates a different set of questions. Once commercial momentum is established, the challenge shifts from building a business to sustaining…
Our next phase of evolution is moving from pure-play generics to something more complex across branded products, biosimilars, and NCEs Punit Patel, President and CEO, of Zydus Americas, speaks about…
What I want, more than anything, is to introduce this modality to patients as quickly and as properly as possible Jaejin Cho, CEO of CellinCells, explains how the company’s proprietary…
Over the past three decades, Taiwan’s elderly population – defined as individuals aged 65 and older – has expanded by a staggering 152 percent. This demographic shift has introduced complex…
Donghoon Lee outlines SK Biopharmaceuticals’ transformation into a global neuroscience player. He discusses the growth of its epilepsy profile, selective expansion into Parkinson’s disease and oncology, and acquisitions. Lee also…
Our goal is to generate rigorous clinical data demonstrating that these therapies can deliver meaningful and lasting benefits for patients For decades, neurological diseases such as Parkinson’s disease, spinal cord…
For years, Europe’s pharmaceutical sector has warned about declining competitiveness. Today, according to Nathalie Moll, Director General of EFPIA, that concern has evolved into something far more urgent. As the…
Vijay Kumar is the acting director of the Office of Therapeutic Products (OTP) within the FDA’s Center for Biologics Evaluation and Research (CBER), the regulatory super office established in 2023…
Heidi Wang, recently retired CEO of OBI Pharma, transitioned from nearly three decades at Bristol-Myers Squibb (BMS) to lead the Taiwanese biotech for close to three years, aiming to advance…
Ajay Mahipal of India-focused healthcare impact and venture capital investment platform HealthKois argues that India’s life-sciences ecosystem is approaching an inflection point. Having built its reputation on manufacturing scale, the…
Michala Fischer-Hansen, EVP and Head of Europe & International Markets at Lundbeck, discusses her return to pharma and Lundbeck’s focused innovator strategy, centred on neuroscience, R&D and growth through regional…
Falling prices are squeezing US generic and biosimilar manufacturers too hard, argues John Murphy III, President and CEO of the Association for Accessible Medicines (AAM). Generic prices have dropped an…
Yoo Jong-man, CEO of Organoid Sciences discusses the company’s pioneering work in organoid-based regenerative medicine, drug evaluation, and precision medicine. He highlights its regulatory achievements, proprietary technology platforms, global expansion,…
The US rare and ultra-rare disease market constitutes a cornerstone of the worldwide pharmaceutical industry, representing a full 52.3 percent of the total global market share in revenue for that…
Our manufacturing base may be local, but the customers we serve and the products we manufacture are truly global Building on decades of microbial manufacturing expertise, Richter BioLogics is scaling…
Just over one year into the second Trump administration, the US healthcare and life science market is navigating a steady stream of series of unprecedented policy shifts. Long defined by…
Europe stands at a critical moment as healthcare systems face growing pressure to accelerate patient access, adapt to more complex therapies, and remain competitive in a global innovation race increasingly…
Our ambition is not simply to bring medicines to market, but to help improve the way dermatology patients are cared for As healthcare systems come under increasing pressure to deliver…
Dr Jeremy Teoh of the Chinese University of Hong Kong leads a research programme spanning bladder cancer biology, surgical innovation, and translational science. From building what is believed to be…
The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather…
D&D Pharmatech is emerging as one of Korea’s most closely watched clinical-stage biotechnology companies, built on more than two decades of research into GLP-1 biology and peptide engineering. With programmes…
America – once the undisputed global leader in medicine manufacturing – is today more reliant on pharma imports than at any time in its history. This dependence has steadily increased…
Establishing a genuine European investment promotion platform is crucial Achim Hartig, Director of Foreign Direct Investment at Germany Trade & Invest (GTAI) and Chair of the OECD Network of Investment…
Japan is resetting itself as a clinical trial destination. Costs have halved, local data requirements are being relaxed, and the country is actively courting the global biotechs that have long…
Sally Epstein looks at why the world’s biggest AI companies are all pivoting towards biopharmaceuticals. Epstein, an entrepreneur in residence at Cambridge Innovation Capital, argues that drug discovery – if…
We have the agility to move quickly, the expertise to navigate complex healthcare systems, and the commitment to bring innovative medicines to patients who are often overlooked Norgine is reshaping…
We want to provide all patients – privately or publicly insured – with rapid access to innovative therapies Germany’s statutory health insurers are under growing pressure to control pharmaceutical spending…
With a career spanning senior roles at Galderma, Pierre Fabre Dermo-Cosmétique, Astellas, and Klinge Pharma, Marion Bock brings cross-channel expertise across prescription, consumer, aesthetic, and medical device categories. IBSA Germany…
Hideyasu Matsuda and Toru Fujieda of the Japan CRO Association argue that, thanks to an updated regulatory framework, Japan is becoming one of the most competitive and operationally attractive clinical…
As cell and gene therapies move closer to broader clinical reality, questions around manufacturing, scalability, and regulatory flexibility are becoming just as important as the science itself. Denise Gavin and…
Europe’s long-anticipated shift to a unified Health Technology Assessment framework is no longer theoretical, it is now being tested in practice. As the results from the first Joint Clinical Assessments…
As Europe rethinks how medicines are priced, regulated, and manufactured, the off-patent sector is moving to the centre of the policy debate. Adrian van den Hoven, Director General of Medicines…
Susan Liao, General Manager of Everest Pharmaceutical Industrial Co., Ltd., represents the second generation of the family business founded in 1978. Trained in pharmacy with a PhD in clinical medicine,…
Stephan Pilsinger, Member of the German Bundestag (CSU) and Deputy Chair of the Health Committee, has publicly criticised the government’s savings package over cuts to organ-donation counselling — even as…
As precision medicine forces biopharma to rethink how it builds, runs, and scales laboratory and manufacturing infrastructure, the industry’s next competitive advantage will be found not in discovery, but in…
Fu Feng Kuo, founder and chief executive of Jyong Biotech and its operational subsidiary Health Ever Biotech, outlines the company’s two-decade journey from botanical raw materials into a NASDAQ-listed pharmaceutical…
The science only matters if we can bring those therapies to the people who need them As ophthalmology enters a new era shaped by aging populations, childhood myopia and medical…
Vera Zheng is Head of Greater China and Head of Asia Pacific Strategy at Parexel, one of the world’s leading clinical research organisations. With a career spanning medical marketing, brand…
Kwunho Jeong, CEO of JNPMEDI, is building an integrated clinical development platform that combines proprietary software, CRO services, and biotech investment to strengthen Asia’s drug development ecosystem. A former consultant…
Gilmore O’Neill, CEO of Editas Medicine, reflects on the company’s evolution from CRISPR pioneer to focused in vivo therapeutics developer. Two years into a strategic pivot, O’Neill shares the reasoning…
Seong-Wook Lee, CEO and founder of Rznomics, has spent more than two decades advancing trans-splicing ribozyme (TSR) technology as a novel RNA editing platform. After nearly 20 years in academia,…
Harshika Sarbajna, SVP Commercial Global at Alvotech, reflects on the evolution of the US biosimilars market and the company’s strategy for scaling access across key therapeutic areas. In this interview,…
Collaboration across institutions is not optional – it is necessary. The pace and complexity of the challenges demand it. As CEO of TUM University Hospital Munich, Dr med Martin Siess…
Dr Long Sheng Fan, CEO, discusses Iridium Medical Technology’s development of a 4,000-pixel bionic retina. By leveraging Taiwan’s semiconductor expertise and AI convolution, the firm addresses retinal degeneration. Currently in…
Hong Kong’s capital markets are entering a more dynamic phase, underpinned by a gradual return of international investors, a maturing innovation ecosystem, and targeted reforms aimed at improving market access…
Gerald Unden, General Manager DACH at Shionogi, believes that healthcare leadership begins with giving the patients of tomorrow a voice in the decisions made today. In this interview, he explains…
Belief BioMed’s Co-Founder and CEO, Dr Jane Zheng, sets out an ambition to move gene therapy beyond scientific promise and into a scalable, globally accessible treatment model. Built on an…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Merck’s $2.13B deal with SciBrunch for KRAS G12D inhibitor SPR2015, Abogen’s $7.78B partnership with Novartis for an mRNA T-cell…
The opportunity now is to ensure that the policy and access environment evolves at the same pace as the science Europe possesses one of the world’s strongest scientific ecosystems, yet…
The debate around Europe’s pharmaceutical future is shifting beyond innovation alone towards the broader challenge of sustaining access, strengthening resilience and creating a more competitive operating environment. Arun Narayan outlines…
Jungmin Rho is the Director of KOTRA – the Korea Trade-Investment Promotion Agency – and one of the organisation’s most seasoned voices on pharmaceuticals and life sciences. With more than…
Professor Do-Youn Oh discusses advances in gastrointestinal oncology, reflecting on the practice-changing TOPAZ-1 trial, Korea’s strengths in clinical research, and the importance of biomarker-driven therapies. She shares her approach to…
It takes a great deal to become number one in a field, but the harder challenge is staying there Joe Henein, CEO of Dubai-headquartered NewBridge Pharmaceuticals, has built one of…
Sidra Medicine is building a vertically integrated academic medical centre where clinical care, research, and education operate as a single system to accelerate precision medicine, particularly in rare and complex…
Can a medicine be considered “available” if it can’t be trusted? As Africa’s manufacturing base expands and its regulatory systems mature, that question is moving to the centre of the…
Steve Kuo, Chairman of TRPMA, outlines Taiwan’s biotech strategy: strengthening clinical trial infrastructure, regulatory alignment and global partnerships. Drawing on experience across academia, government and diplomacy, he emphasises cultural change…
We need to bring together expertise in medicine, bioengineering, production technology and artificial intelligence Germany has the scientific expertise and clinical infrastructure to lead in cell and gene therapy, yet…
Childhood cancer survival rates in high-income countries now exceed 80 percent, but that masks a more uneven picture: paediatric drug development lags far behind adult oncology, follow-up and psychosocial care…
Scientific breakthroughs are redefining what is possible in cancer care, yet the true test lies in translating discovery into meaningful and lasting patient benefit. Michael Baumann reflects on how the…
The European Commission has set itself an ambitious target: making Europe the world’s most attractive destination for life sciences by 2030. In recent conversations with PharmaBoardroom, executives leading Europe for…
Jurie Hwang is the Director of Public & International Affairs of KoreaBIO, the largest and most broadly constituted life sciences industry association in South Korea. With 650 member organisations spanning…
We have set a goal that by 2027, more than 740,000 Korean patients will be benefiting from our treatments Christoph Hamann, General Manager of Merck Healthcare Korea, highlights strong momentum…
Amgen’s trajectory in Hong Kong reflects a broader shift underway across the territory’s healthcare landscape, where data-driven care and cross-sector collaboration are converging to accelerate access to innovation. Against the…
Multi-million dollar deals, world-first approvals, and a new willingness to be patient are transforming how Korea’s biotech sector does business. Korean biotech companies want to hold onto their molecules for…
Thomas Madden is the CEO of Acuitas Therapeutics, the lipid nanoparticle delivery technology company whose platforms underpinned some of the most significant advances in mRNA medicine, such as the COVID-19…
As the global clinical development landscape becomes more fragmented and competitive, biotechs increasingly need partners that can help them navigate regulatory complexity, identify the right trial locations, and generate meaningful…
Dr Ali Taher, MD, PhD, FRCP, has spent more than three decades shaping the understanding and treatment of thalassemia. As Associate VP for Academic Centers at the American University of…
Taiwan’s investment culture remains heavily oriented toward semiconductors and electronics, and few investors are yet convinced to commit capital to biotech Dr. Lin, Founder and Chief Scientific Officer of Tripartite…
CirCode Biomed is emerging at the forefront of a small but fast-evolving field seeking to turn circular RNA into a new class of medicines. From its roots in pioneering academic…
Korea is a highly developed and extraordinarily fast-moving market; you simply cannot afford to lag behind Marc Franck, Managing Director of Zuellig Pharma Korea, explains why Korea has become one…
Dr David J. Rawlings is the division head of immunology at Seattle Children’s and director of the Center for Immunity and Immunotherapies at Seattle Children’s Research Institute. An immunologist and…
Jaw-Jou Kang, Professor at NYCU, former head of Taiwan’s Food and Drug Administration and current chair of the Taiwan Society of Regulatory Affairs for Medicinal Products discusses the nation’s regulatory…
My long-term hope is that dialysis will become much less common because we are able to diagnose and treat kidney disease earlier and more effectively Prof. Dr. Jörg Latus is…
Leonard Paolillo, President of Merz Therapeutics North America, shares what it means to be a growing player in the specialty neurology space. Two years after the company’s acquisition of INBRIJA®…
Jinhak Kim, Executive Director and President US at C&R Research, describes the company’s evolution into a global, data-driven CRO. He outlines its strategy of matching clinical trials to regions based…
Semiconductors: Silicon Powerhouse Taiwan and semiconductors – the microscopic chips inside virtually every electronic device – are inextricably linked. For a modestly sized island, Taiwan’s semiconductor dominance is extraordinary: through…
We have spent the past decade building a strong foundation, investing in the market, expanding our capabilities, and assembling an exceptional team The US generics industry remains central to the…
James Park discusses Lotte Biologics’ strategy to establish itself as a global CDMO through dual manufacturing hubs in the US and Korea, advanced biologics and ADC capabilities, and a strong…
In recent years, Taiwan’s policymakers have been aggressively deploying a multi-layered industrial strategy – and doing so with the benefit of watching earlier regional movers stumble – in an effort…
Korea has something that very few countries can claim: high-quality healthcare data at genuine population scale JK Lee, Vice President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), outlines…
Professor Stefan Vieths, president of Germany’s Paul-Ehrlich-Institut (PEI), explains how Europe’s most specialised biomedicines regulator is navigating a period of rapid transformation. Vieths traces the PEI’s 130-year evolution from a…
If price is the only basis for adoption, biosimilars will not survive as a viable industry Tom Newcomer, SVP & Head of US Commercial, Samsung Bioepis, discusses the company’s evolution…
I want Wacker Biotech to be recognised for its scientific expertise, speed, collaboration, and flexibility The expectations placed on today’s CDMOs extend far beyond manufacturing capacity, demanding scientific expertise, integrated…
The EU Health Technology Assessment Regulation was implemented in January 2025 to replace 27 fragmented national evaluations with a single Joint Clinical Assessment, run in parallel with EMA review. The…
Axolabs has spent more than two decades building expertise in a field that is only now beginning to reach greater clinical and commercial scale. Under CEO Susanne Leonhartsberger, the specialist…
Chinese pharmaceutical companies are increasingly seeking drug approval in the EU, US, and Australia, beyond the NMPA. Daphne Smyth of Veristat has witnessed this shift firsthand, advising sponsors on data…
Innovation cannot stop at the laboratory door. It must extend to how therapies are developed, approved, and reimbursed Brian Campbell, Vice President and General Manager of the US for Orchard…
Europe’s place in the global biotechnology race is entering a decisive phase. Scientific excellence and industrial depth remain powerful advantages, yet intensifying competition from the United States and China is…
Legend is looking at all ways to bring CAR-T to more patients, including allogeneic, autologous, and in vivo approaches Alan Bash, Interim CEO of Legend Biotech speaks about achieving the…
As the US biosimilar market matures, Samsung Bioepis is accelerating its expansion, with ten FDA approvals so far, seven assets in development, and an ambitious target of 20 products on…
Dr Lasse Lehnert, General Manager of Chugai Pharma Germany and European Director for Customer Engagement and Digital Experience, discusses the unique Roche-Chugai strategic alliance, the challenges for continued delivery of…
In 2026, regulation, policy, institutions, and expertise are aligning to ensure Hong Kong can be a player in an extremely competitive Asian clinical trials landscape. From real-world data studies to…
CAR T-cell therapies are entering a new phase of development in which the focus is increasingly shifting from scientific validation towards the practical realities of access, scalability, reimbursement, and delivery…
A new generation of biotechnology companies is beginning to rethink the foundations of drug discovery. At the intersection of population genomics, biomarker-driven trials, and artificial intelligence, Halia Therapeutics is exploring…
Joshua Salsi, Head of North America, Biocon Biologics explains the company’s evolution into an integrated, global biosimilars company following the 2022 Viatris portfolio reacquisition. He highlights the company’s growing US…
Germany’s research-based pharmaceutical industry is approaching a defining period as mounting pressure to curb healthcare expenditure clashes with the country’s long-established ambition to remain a leading hub for innovation, scientific…
Europe’s position as a global healthcare leader is being tested by intensifying competition from both the US and China. As CSL’s Dirk Hoheisel points out, this is not because Europe…
Great success stories take time, great science, resilience. We built Denali with the goal of being one of those companies, not just surviving, but ultimately thriving. Ryan Watts is the…
Recordati Rare Diseases aims to be a trusted partner in helping patients with rare diseases reach diagnosis and appropriate care sooner Rapid access to innovation alone does not solve the…
Khaled Elrefae of Recordati Rare Diseases discusses how the company is expanding its rare disease footprint across Saudi Arabia, the GCC, and the wider MENA region. He highlights the region’s…
Ken Lee, Managing Director for Asia Pacific Clinical Business at Syneos Health, draws on a 20-year career across pharma, medicine, and CROs in Europe and Asia. He highlights Asia Pacific’s…
Innovation, supply security, and sustainability are intertwined challenges for healthcare systems across Europe. For CSL, these conversations are part of everyday reality, from ensuring access to plasma-derived therapies and advancing…
The biosimilars market is constantly evolving, so our teams need the willingness to learn, adapt, and embrace new ways of working Germany is playing an increasingly important role in Biocon’s…
Singapore’s Health Sciences Authority has become one of the world’s most respected drug regulators, earning WHO maturity level 4 status and a seat at tables like the Access Consortium and…
I believe we can position Korea as a true global leader in biohealth innovation Lee Hyung Hoon, Vice Minister at Korea’s Ministry of Health and Welfare, outlines his vision for…
Novo Nordisk has rebranded as ‘Novo’ and plans to enter new therapeutic areas as part of CEO Maziar Mike Doustdar’s push to reinvigorate growth. The company has already reinvented itself…
Dr Jeongseok Lee has served as President of the Korea Biomedicine Industry Association (KoBIA) since September 2020, backed by an outstanding 35-year career in public service and longstanding leadership in…
Dr Tawfeg Ben-Omran, Division Chief of Genetic and Genomic Medicine at Sidra Medicine, discusses Qatar’s pioneering advancements in rare disease treatment. He explains how whole genome sequencing and expanded newborn…
For many years, the US has been considered the unequivocal champion in the global war against cancer. Not only does the country presently account for approximately 57 percent of worldwide…
Although best-known for its dermo-cosmetics, pharmaceuticals account for 50 percent of Pierre Fabre’s revenues, and the company has been engaged in cancer care for almost half a century. Now, it…
Germany and Europe have every reason to remain optimistic, provided we build on the strengths we already have As Europe seeks to strengthen its pharmaceutical resilience and Germany redefines its…
China has built one of the world’s most advanced digital health ecosystems — large, fast-moving, and integrated across hospitals, internet platforms, insurers, pharmaceutical companies, and regulators. AI is now embedded…
Majid Jafar, Co-Founder of the Loulou Foundation, discusses the strategic evolution of the patient research organisation that he co-founded with his wife following their daughter Alia’s diagnosis with CDKL5 Deficiency…
Mathias Hevert, third-generation leader of Hevert-Arzneimittel, has guided the family-owned company as CEO for more than 20 years. Founded in 1956, Hevert specialises in naturopathic medicines, including homoeopathic combination remedies,…
Medicines regulatory agencies face enormous challenges in supporting and maintaining the safety, quality and supply of therapeutic goods in their respective countries and regions. Professor Anthony (Tony) Lawler, head of…
Against a backdrop of rising geopolitical tension, regulatory fragmentation, and mounting pressure on Europe’s healthcare systems, Prague-headquartered Zentiva is positioning itself as a distinctly European pharmaceutical player focused on long-term…
David Meek, CEO of Genetix Biotherapeutics, discusses the company’s evolution from a scientific innovator into the commercial leader in curative therapy. He outlines how Genetix is scaling access to its…
What begins as frustration with the limits of academic research has developed into a story of entrepreneurship, scientific translation and sustainable biotech growth. Dr Thomas Schirrmann, Co-Founder and CEO of…
Hans Duijf, General Manager of Novo Nordisk Taiwan, has spent his entire 28-year career with the Danish pharmaceutical company, a rare tenure in today’s era of executive mobility. Duijf has…
Hisham Hagar is the executive country manager for Vertex Pharmaceuticals across the Gulf Cooperation Council, leading efforts to expand access to genetic therapies and strengthen healthcare partnerships in the region.…
In debates over drug pricing, affordability and innovation are often framed as a zero-sum trade-off. Zeba M. Khan, Editor-in-Chief of ISPOR’s Value & Outcomes Spotlight, argues it doesn’t have to…
Access works when all pieces are in place. Hearing directly from patients about what diagnosis or how a treatment impacts their lives is meaningful to everyone involved Scott Weintraub, Head…
Drawing on a career spanning oncology drug discovery at AstraZeneca and biotech leadership as CEO of Enhanc3d Genomics, Hazel Jones is now Chief Strategy Officer at Laverock Therapeutics. We caught…
Chris Posner, President of Esteve Pharmaceuticals LLC, the US affiliate of Spanish specialty player ESTEVE, speaks about the process of building its US affiliate from the ground up since joining…
Andreas Schuil, Vice President & General Manager EMEA at Orchard Therapeutics, discusses the company’s gene therapy for metachromatic leukodystrophy, a devastating ultra-rare paediatric disease. He highlights challenges in access, pricing…
After six years leading the French Healthcare Alliance China, Olivier Dessajan has watched the Franco-Chinese healthcare relationship transform beyond recognition; from a one-way flow of products and partnerships into something…
Biosion has built a distinctive position within the new generation of Chinese biotech companies pursuing more capital-efficient, globally connected growth. Built around antibody innovation, early value creation, and selective partnering,…
Korea’s real strength right now is active, innovative discovery research, and that expertise, along with international networking, keeps improving Jungwon Woo, MedPacto CEO, discusses translating innovative cancer research into clinical…
The Middle East contains one of the world’s strongest concentrations of expertise in the rare blood disorder thalassaemia. The story starts with the high prevalence of this disease in the…
Mirjam Mann, Managing Director of the German Alliance for Chronic Rare Diseases (ACHSE), discusses Germany’s progress and persistent gaps in rare disease care. She highlights a challenging landscape, with fragmented…
As Synthon celebrates its 35th anniversary, the Dutch-headquartered complex generics specialist is entering a new phase of its evolution in the pursuit of affordable medicines worldwide. Having accelerated growth over…
Innovators should hold CDMOs to a high bar, and CDMOs need to step up Syed T. Husain, Chairman & CEO of Made Scientific, outlines the organization’s differentiated strategy to disrupt…
Nearly six years after becoming a standalone business, Merz Therapeutics is expanding beyond its neurotoxin heritage to build a broader specialty neurology platform across Europe and internationally. Newly appointed Region…
Europe is rewriting the rules governing medicines, innovation, and industrial competitiveness, with consequences that reach far beyond regulation alone. Pricing pressure from the United States, slower market access, rising administrative…
TLC Bio’s George Yeh outlines the company’s evolution from liposomal oncology roots to advanced lipid nanoparticle platforms, including sustained-release therapies and in vivo cell therapy. He highlights a globally integrated…
Dr Abdulrazaq S. Al-Jazairi, Director of Clinical Trial Transformation at King Faisal Specialist Hospital and Research Centre, has spent more than 30 years at the institution. Trained as a cardiology…
Thomas Seewoester, Vice President Site Operations and Site Head at Amgen Manufacturing Limited, LLC, has overseen Puerto Rico’s most significant manufacturing campus for three years, building on more than three…
The US Food and Drug Administration (FDA) finds itself in the midst of unprecedented political turmoil. The Trump Administration’s Department of Government Efficiency (DOGE) removed 3,500 of the Agency’s 20,000…
Boston and the Bay Area are globally renowned life science hubs, but beyond these more well-known centers of excellence lies a dense network of states and cities with enticing and…
The priority should be to ensure that reimbursement systems can support sustainable healthcare budgets, timely patient access and continued pharmaceutical innovation Delivering the first approved treatment for metabolic dysfunction-associated steatohepatitis…
Prof Dr med Hanns-Peter Knaebel has moved between the operating table, industry, and hospital leadership in his career a path that now shapes his approach to one of the more…
Eight years into its shift into rare diseases, Ferrer is moving into a new phase as its pipeline matures. CEO Mario Rovirosa reflects on the setbacks and lessons shaping that…
Taiwan’s population of just 23 million people and contested political status should, in theory, harm its chances of becoming a globally relevant clinical trials hub. In fact, these two factors…
Even a truly great medicine delivers limited value if patients cannot actually benefit from it Jeong Tae Kim, General Manager of Daiichi Sankyo Korea, has spent 18 years with the…
Dr. I-Shu Lee, founder and CEO of Vitae Biomedical, began his career as a postdoctoral researcher before making the uncommon leap from academic laboratory to entrepreneurship in 2019. Built around…
Mohamed ElShaarawy, General Manager for the United Arab Emirates at Roche Pharmaceuticals, reflects on the organisation’s role as a long-term healthcare partner aligned with the country’s ambition to build a…
Hong Kong’s biotech capital market has completed one of the more dramatic reversals in recent years. After a brutal two-year drought in which valuations collapsed, liquidity evaporated, and companies were…
Switzerland and South Korea may be separated by thousands of kilometres, but their economic relationship has never been closer. Bilateral trade reached nearly USD 8 billion in 2025, pharmaceutical flows…
DACH should become a powerhouse for the Group Germany is emerging as a key growth and launch market for Ipsen, with the DACH region now ranking as the Group’s leading…
Once regarded as a strategic afterthought by international biopharma, the Middle East has undergone a profound transformation in recent years, emerging as an early adopter of next-generation therapies for rare…
After years of foundational investment in genomics, population screening, and rare disease diagnostics, Gulf nations are entering a transformative era: the delivery of advanced therapeutics. The cell and gene therapy…
Prof Dr Markus M. Lerch, Physician-in-Chief and CEO of Munich University Hospital, oversees more than 2,000 concurrent clinical trials and a EUR 2.2 billion campus rebuild now underway in Bavaria.…
Leo Shen, General Manager of Heron Neutron, transitioned from PwC and semiconductors to healthcare, leveraging regulatory, operational, and capital-market expertise to scale boron neutron capture therapy (BNCT). Under his leadership,…
Seven months into the job as CEO of GSK, Luke Miels has moved faster and bigger than most expected. Having laid out an M&A strategy based around small bolt-ons at…
ESTEVE has successfully reshaped itself in the recent years as an integrated healthcare company with two distinct growth engines: highly specialised pharmaceuticals and a global small-molecule CDMO platform, united by…
A quarter-century after the Human Genome Project revolutionized biology, genomic sequencing has matured from an ambitious scientific frontier into an indispensable clinical reality. Today, molecular insights routinely guide everything from…
We have evolved well beyond the traditional CRO model Global biopharma companies are looking at Japan through a different lens, seeking partners that can navigate an increasingly complex regulatory landscape…
You cannot choose between performing and transforming. The organisations that succeed can do both As AI, shifting healthcare policy, growing pressure around affordability and access, and rapidly evolving models of…
Europe accounts for a substantial share of Takeda’s business, hosts a significant slice of the company’s manufacturing footprint, and is involved in around half of its late-stage trials and priority…
Randy Pritchard, General Manager and Senior Vice President of Clinical Operations for North America at bioMérieux, a global leader in in vitro diagnostics, speaks about the outsized strategic weight of…
Germany’s Medical Research Act is almost two years old. Writing in the June/July 2026 edition of DIA Global Forum, Thomas Sudhop, Claudia Riedel and Karl Broich of the Federal Institute…
Joe Yeh describes founding aetherAI to digitise pathology and embed AI into routine diagnostics, addressing inefficiency, subjectivity, and missed disease detection. He explains Taiwan’s rapid adoption, a research-driven market access…
Tina Graves, General Manager of GSK Taiwan, reflects on the affiliate’s strong commercial performance, the strategic shift towards specialty care and oncology, and the urgent case for repositioning adult immunisation…
We are actively evolving into a nation that discovers innovative drug candidates Korea’s clinical trial sector has spent the past two decades transforming itself from a fast follower into one…
Petar Vazharov, CEO of Lotus Pharmaceuticals, is a medical doctor with an MBA who joined Alvogen in 2009 as one of its first international hires. After building the company’s Central…
Contemporary Taiwan finds itself navigating unprecedented healthcare challenges, having transitioned into a super-aged society with unexpected speed, compounded by one of the lowest birth rates globally. In 2024, to secure…
A biochemistry PhD, Bin Li started out in Merck’s research labs before transitioning to Wall Street, where he was one of the few figures with the scientific, financial, and linguistic…
Healthcare transformation across the GCC is entering a new phase, driven by major investments in precision medicine, genomics, and healthcare system modernisation, with countries such as Saudi Arabia and the…
Access to capital is the difference between life and death for small biotechs and life science start-ups. But in an industry with high levels of failure and decades-long development cycles,…
With the bioPROTAC platform, we can, in principle, degrade essentially any problematic protein Jaehyun Choi, Co-CEO of Genexine, outlines the company’s transition from its established hyFc platform towards bioPROTAC, a…
Dr Long Jiang is the CEO of GCP ClinPlus, a Chinese CRO with operations in New Jersey. A former cardiovascular surgeon at Peking University People’s Hospital, he shifted into clinical research…
Pamela Gavin, CEO of the National Organization for Rare Disorders, discusses NORD’s origins in the advocacy movement that led to the Orphan Drug Act and its current mission to improve…
A shift is underway in how rare diseases are identified and managed across the Middle East and North Africa, as stronger diagnostic capabilities, evolving access frameworks, and growing local expertise…
Whilst G7 countries have long been the traditional homes of pharmaceutical innovation, there is increased global competition, and a real risk that this longstanding leadership will be lost without concerted…
The biggest opportunity is to dare more, invest in promising ideas and become better at translating our excellent science into successful businesses Germany has no shortage of scientific expertise, but…
Our objective is to navigate ongoing healthcare reforms successfully, serve as a primary growth engine for Viatris in Europe, and maximize our contribution to patient care Simon von Boeselager, Country…
When Nasha Fitter’s daughter, Amara, was diagnosed with the ultra-rare FOXG1 syndrome at just seven months old, the prognosis was stark: no speech, no independent movement, severe intellectual disability, and…
After a rocky couple of years, Hong Kong has defied its sceptics and definitively bounced back. As Asia’s financial capital and the bridge between mainland China and international markets, the…
A sustainable market for generics and biosimilars is the key to lowering the cost of medicine in the US, says John Murphy III, President and CEO of the Association for…
Translating scientific breakthroughs into products that genuinely impact patients is more challenging than it has ever been. Only ten percent of drugs that enter clinical trials ever make it all…
Patients in Japan deserve the same access to innovative treatments that patients in other markets have. Accelerating that access is what drives us Noriyuki Takai, CEO of EPS Corporation, outlines…
The rare disease landscape is becoming increasingly sophisticated, demanding not only scientific innovation but also new approaches to access, evidence generation and patient support. Recordati Rare Diseases has built its…
There is a real sense of energy and ambition across the Korean biopharma industry Sungphil Kim, General Manager of Cytiva Korea, discusses his vision for strengthening Korea’s biopharma ecosystem through…
Hong Kong is repositioning itself within the global innovation landscape, moving beyond its total market-driven model to take an industry policy oriented market-driven approach. Through Office for Attracting Strategic Enterprises…
Mohamed Abu Shawish of Kyowa Kirin discusses how the company is reducing the time to diagnosis for rare diseases, increasing patient identification, and building local capacity across the GCC. He…
Genmab is moving into one of the most consequential chapters in its history, as decades of antibody innovation converge with an ambition to take greater ownership of the journey from…
Germany’s biotechnology sector finds itself at a critical inflection point as political ambition, scientific strength, and industrial policy begin to converge around a shared objective: positioning the country as a…
The 2024 combination of 3P Biopharmaceuticals and Biovian gives 3PBIOVIAN greater scale and a broader technology base as Dámaso Molero Sánchez looks towards the CDMO’s next phase of growth. He…
Amy Adams stepped into the role of director of the National Institute of Neurological Disorders and Stroke (NINDS) at the beginning of the year after more than two decades within…
As China’s biotech industry races into next-generation modalities, Epigenic Therapeutics is seeking to open a new frontier by regulating gene expression without cutting DNA. In conversation with Bob Zhang, the…
More than 40 years ago in 1983, the Orphan Drug Act was passed in the US to support and incentivise the development of rare disease therapies. Despite the over 6,000…
New Takeda CEO Julie Kim inherits a firm with flatlining growth and generic competition eating away at its lead drug’s revenues. Will three major new launches over the next year…
As SyntroMed approaches its 100-year milestone, the company is entering a decisive phase of transformation, moving beyond its established OTC foundations to build a more innovation-led and internationally connected organisation.…
Despite its modest market size, Taiwan is proving a popular investment destination for pharma and medtech multinationals. While the island’s semiconductor industry garners more headlines and revenues, life sciences is…
The opportunity to continue growing the organisation, while driving performance and innovation, remains a strong source of motivation Sobi’s rapid growth in Germany and across DACH-NL is opening a new…
Pamela Hoffman is the president and recently appointed CEO of Padagis, a US-based generic pharmaceutical company established following the divestiture of Perrigo’s generics business. With manufacturing operations in Minnesota and…
But Korea is genuinely active, with strong resources – scientifically sound, capable, and very motivated Kyong Hwa Park, Professor of Medical Oncology at Korea University College of Medicine, reflects on…
Sen Kuei Yeh, Chairman of Ta Fong Pharmaceutical, is the second-generation leader of one of Taiwan’s established domestic manufacturers. Joining in the 1990s, he assumed leadership in 2016 after gaining…
A genuinely healthy lifestyle can help prevent neurodegenerative disease Charles S.Y. Yang discusses how his background in physics and quantum sensing led to the founding of MagQu, pioneering ultra-sensitive blood…
Few European pharmaceutical companies have undergone a transformation as striking as STADA’s. From its roots as a German generics business, the group has evolved into a diversified healthcare player with…
Diabetes is surging in Africa. But, in a continent where healthcare systems are set up to support treatments for infectious – not non-communicable – diseases, can pharma companies step up…
Randy Teel, President and CEO of Arvinas, outlines the company’s evolution from a Yale-founded research platform into a leader in targeted protein degradation. He explains how Arvinas is working to…
We believe that flexibility, analytical drive, initiative, and a detailed, hands-on mindset are more important than industry experience Peter Gerckens, CEO at PharmaSGP combines a strong background in consulting, branding,…
Kelly LoBianco, founding director of the Los Angeles County Department of Economic Opportunity, discusses how the agency is driving growth of the region’s life sciences sector. She outlines LA County’s…
New legislation is putting Germany’s status as Europe’s most innovation-friendly pharma market under severe threat. Germany has long led Europe in terms of both the number of new medicines…
For two decades the case for running a clinical trial in Asia was essentially arithmetic: the same study, for less money. That argument has not gone away, but it is…
With US-China geopolitical tensions pushing multinational pharma to seek manufacturing bases outside China, does Taiwan’s CDMO sector offer a compelling alternative? Recent US policy moves could reshape the global…
Hong Kong is entering a more decisive phase in its innovation journey, as Terry Wong steers HKSTP towards greater economic value and global relevance. With a stronger focus on translating…
A 2025 collection of perspectives from over 30 biopharmaceutical industry stakeholders finds that while patient centricity has made real progress — moving from an afterthought to an expectation in the…
The first thing I’d say to innovators is to ask the patients. Patient groups are ready to support innovation, make sure we’re measuring what matters, and delivering what’s meaningful Avril…
Chinese biotechs are now outpacing multinationals at getting drugs into pivotal trials — but MNCs still win the race to final approval. In this piece from the September 2026 edition…
The European Health Data Space (EHDS) is a landmark regulation designed to unify health data across the EU for both direct patient care and medical research. Writing in the April…
Five conferences, anxiety spreading across five continents, one unmistakable pattern: the global pharmaceutical industry is transforming at a dizzying pace. From Philadelphia to Geneva, from Istanbul to Chicago and London,…
We have set out a clear strategy, but strategy only provides direction; ultimately, trust is built through execution Europe pioneered the biosimilars industry and remains its most advanced market, yet…
Biosimilars have already saved health systems billions of dollars, yet adoption still varies wildly by geography. With a wave of major biologics losing patent protection this decade, the market opportunity…
Dr Maisha Draves, Associate Executive Director of The Permanente Medical Group (TPMG), speaks to the group’s approach to integrating the use of biosimilars across the care network. By focusing on…
Germany remains one of Europe’s most important pharmaceutical markets, combining scientific excellence, strong clinical research capabilities, and early access to innovation. Yet as breakthrough therapies become more sophisticated and global…
Transformation often reveals itself not through grand declarations, but through the decisions organisations make about where to invest, what capabilities to build, and how they choose to serve patients. At…
Tomas Mihal, General Manager for Germany at STADA, discusses the company’s diversified three-pillar model across consumer healthcare, generics and specialty medicines, highlighting its strong German market position, agile culture and…
Keren Haruvi, President of Sandoz North America, reflects on the company’s transformation following its spin-off from Novartis and outlines how Sandoz is positioning itself at the forefront of the evolving…
Serdar Yüksel spent two decades as a nurse before 15 years in North Rhine-Westphalia’s state parliament, and now represents the SPD on the Bundestag’s Health Committee. He discusses the jump…
The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for…
Germany is the default first-choice European market for launching new, innovative medicines. But with the country’s pricing system under growing strain from both national and international pressures, some in the…
Chrys Kokino, President of Accord North America, discusses the strategic evolution of the US biosimilar market and Accord’s mission to move beyond single-asset competition toward a comprehensive treatment portfolio. Drawing…
At its core, we need a reform of the welfare state. It’s indispensable, but it needs to be brought back to its core purpose: help for those who need it…
Xia JIN, co-founder & CEO of Hong Kong-based immunology biotech Immuno Cure, outlines the progress of its DNA vaccine platform, highlighting strong Phase I results for an HIV therapeutic vaccine…
Rock-bottom prices, regulatory red tape, and intense competition from Asia have made life difficult for Europe’s generics and biosimilar producers. Yet a handful of companies are not just surviving this…
What motivates me is the opportunity to improve medical practice in a meaningful way, rather than simply bringing another product to market In an industry where genuine differentiation is becoming…
It is not unreasonable, at first glance, to ask why so many pharma multinationals have chosen to establish standalone affiliates in Hong Kong. After all, only 7.5 million people call…
The European Union is in the midst of the biggest shake-up of its pharmaceutical rulebook in a generation, racing to secure supply chains, speed up drug development, and keep Europe…
Korea’s position as a clinical trials hub did not happen overnight. The country has treated clinical development as a matter of deliberate government policy for the better part of two…
As the world around us changes, we need to change with it Marie Antonia von Schönburg has been President and Chief Executive of the Korean-German Chamber of Commerce…
Growth in rare diseases is measured differently. It is not simply about launching new products, but about improving diagnosis, strengthening healthcare partnerships, and supporting patients throughout their journey. Those principles…
Long regarded as a clinical trials backwater, the Middle East has experienced a tremendous surge in clinical research over the past five years. This boom is fuelled by a global…
Mohit Manrao, SVP and Head of US Oncology at AstraZeneca, leads the company’s effort to drive impact for cancer patients across the US. He elaborates on what it means to…
Cell and gene therapies (CGTs) can now cure diseases that were untreatable a decade ago, often with a single dose. Yet most eligible patients – even those in rich countries…
Lee-Cheng (LC) Liu, CEO of EirGenix, reflects on the evolution of Taiwan’s biotech sector and the company’s role within it as both a biologics CDMO and biosimilar developer. Liu discusses…
Cancer is becoming one of Europe’s defining public health and economic challenges, forcing policymakers to think far beyond treatment alone. Questions of prevention, screening, innovation, equitable access, system resilience, and…
Germany’s future competitiveness begins with the policy decisions we make today Scientific breakthroughs alone are not enough to shape the future of healthcare. They must be matched by the right…
Honeybear Biosciences is emerging as a pioneering force in precision oncology, leveraging its proprietary CoNectar glycan conjugation platform to advance next-generation ADCs and ARCs. Guided by a globally experienced leadership…
Taiwan runs one of the most cost-effective universal healthcare systems in the world, delivering near-universal coverage to 23 million people at a fraction of what comparable systems cost elsewhere. At…
Kris Hager, general manager of Bristol Myers Squibb Taiwan, discusses aligning global growth strategies with local market dynamics. With 60 years of presence in Taiwan, BMS is focused on launching…
H.E. Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, sets out the emirate’s ambition to build the world’s most integrated and intelligent healthcare system.…
Hong Kong – already Asia’s finance hub and an increasingly robust life science R&D destination – is placing huge bets on becoming the region’s prime location for developing, financing, and…
See our Cookie Privacy Policy Here
